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Abstract  
Oral lichen planus (OLP) and recurrent aphthous stomatitis (RAS) are chronic inflammatory 
conditions often characterised by erosive and/or painful oral lesions that have a considerable impact 
on quality of life. Current treatment often necessitates the use of steroids in the form of 
mouthwashes, creams or ointments, but these are often ineffective due to inadequate drug contact 
times with the lesion.  Here we evaluate the performance of novel mucoadhesive patches for 
targeted drug delivery. Electrospun polymeric mucoadhesive patches were produced and 
characterised for their physical properties and cytotoxicity before evaluation of residence time and 
acceptability in a human feasibility study. Clobetasol-17-propionate incorporated into the patches 
was released in a sustained manner in both tissue-engineered oral mucosa and ex vivo porcine 
mucosa. Clobetasol-17 propionate-loaded patches were further evaluated for residence time and 
drug release in an in vivo animal model and demonstrated prolonged adhesion and drug release at 
therapeutic-relevant doses and time points. These data show that electrospun patches are adherent 
to mucosal tissue without causing tissue damage, and can be successfully loaded with and release 
clinically active drugs. These patches hold great promise for the treatment of oral conditions such as 
OLP and RAS, and potentially many other oral lesions.  
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Introduction 
Oral lichen planus (OLP) and recurrent aphthous stomatitis (RAS, also termed aphthous ulcers) are 
common debilitating lesions that affect the mucosal lining of the oral cavity. OLP, a chronic 
inflammatory disease, affects 1-3% of the world ?s population causing bilateral, white striations, 
papules or plaques, whereas RAS presents as painful, round, shallow ulcerations of the mucous 
membrane, causing substantial morbidity in a reported 25% of the world ?Ɛ population at some point 
in their lifetime [1, 2]. The pathogenesis of both conditions is not entirely understood and 
consequently they lack effective clinical management. Current treatment is dependent on immune-
modulating steroids to reduce inflammation and pain that are delivered either systemically, which 
although effective, rapidly induces unacceptable side effects leading to cessation of treatment or 
alternatively delivered topically by mouthwashes or gels. These topical dosage forms are generally 
considered suboptimal due to the continuous flow of saliva and mechanical stresses within the oral 
cavity that result in the active substance being washed away, leading to shorter exposure times and 
unpredictable drug distribution [3]. For localised controlled delivery, it is necessary to prolong and 
improve the contact time between the drug and the mucosal lesion, and this has driven the 
development of a number of mucoadhesive delivery systems including particulates [4, 5], tablets [6, 
7], films [8-10] and patches [11]. Oral patches are usually laminates consisting of an impermeable 
backing layer and a drug-containing bioadhesive layer for mucosal attachment, and have typically 
been prepared using solvent casting [12] or hot melt extrusion techniques [13]. Recently, 
investigations by others and us have focussed on electrospinning as an innovative method to 
produce mucoadhesive patches [14-17]. Electrospinning is a highly versatile fibre and membrane 
manufacturing method that enables the unique combination of polymers, solvents and other 
molecules in ways that offer the ability to tune the physical structure and biological functionality of 
the resulting structures, which cannot easily be achieved with other conventional manufacturing 
techniques [18]. Furthermore, electrospinning produces patches that structurally can be composed 
of both nano- and microscale fibres, creating a high porosity and surface area for drug bioavailability 
and enabling a high level of interaction with the epithelium of the oral mucosa.  
We recently reported the successful fabrication of a novel electrospun dual-layer mucoadhesive 
system comprising of an outer hydrophobic polycaprolactone (PLC) backing layer and an inner, 
mucoadhesive component formed by electrospinning polyvinylpyrrolidone (PVP) and Eudragit® 
RS100, as fibre-forming polymers. Particles of polyethylene oxide (PEO), were also added to the 
inner layer, to enhance the mucoadhesive properties of the structure [14]. Combining Eudragit® 
RS100, a copolymer of ethyl acrylate, methyl methacrylae and trimethylammonioethyl methacrylate 
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chloride with the PVP was shown to reduce membrane solubility and allowed control over the 
structural integrity of the patches upon hydration. This combination of materials produced a highly 
flexible, nano-fibre-forming matrix with a large surface area that showed strong mucoadhesive 
properties in an ex vivo model [14]. The system, once loaded with drugs, has the potential to provide 
greater therapeutic efficacy via highly localised and controlled drug delivery to the mucosal surface  
Several recent reviews on OLP and RAS management suggest that the best treatment remains high-
potency topical corticosteroids, acting to modulate the dysregulated immune response [19, 20]. 
Among those studied, clobetasol-17-propionate has been shown to be a highly effective topical 
steroid, with 95% improvement in patients with OLP after 2 months of therapy [21] and complete 
remission with no major side effects in patients with persistent RAS [22].  Clobetasol-17-propionate 
is currently only available formulated as topical preparations (mouthwash, mousse, ointment or 
emollient cream) that have low aqueous solubility and minimal oral bioavailability [23].   
To summarise, oral lichenoid reactions and recurrent aphthous stomatitis together represent unmet 
clinical needs in oral medicine. While steroids are generally the drugs of choice, site-specific targeted 
delivery is a major challenge in the wet environment of the human mouth. The aim of this study was 
to examine the physico-chemical and mucoadhesive properties of our recently developed, 
electrospun patch [14] designed to address this problem, and to evaluate the clinical acceptability of 
the system at three intraoral locations (buccal, gingivae and tongue) in a human healthy volunteer 
study. Drug release from the patches was determined for clobetasol-17-propionate by measuring 
dissolution rates in an in vitro tissue-engineered oral mucosa system and an ex vivo porcine mucosa 
model. Finally, the clobetasol-17-propionate loaded patches were evaluated for residence time and 
drug release in an in vivo animal model. 
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2. Materials and Methods 
2.1 Manufacture of mucoadhesive patches 
2.1 Materials 
Polyvinylpyrrolidone (MW 2,000 kDa; PVP) was a gift from BASF (Cheadle Hulme, UK).  Eudragit 
RS100® was a gift from Evonik Industries AG (Essen, Germany). Poly(ethylene oxide) (MW 2,000 kDa; 
PEO), poly(caprolactone) (MW 80 kDa; PCL), and clobetasol-17-propionate (analytical standard, CP) 
were purchased from Sigma Aldrich (Gillingham, UK).  Ethanol (EtOH), dichloromethane (DCM) and 
dimethylformamide (DMF) were purchased from Fisher Scientific (Loughborough, UK). 
 
2.2.1 Fabrication of mucoadhesive patches 
Electrospun materials were fabricated commercially (Bioinicia, Spain) or in-house using 
electrospinning equipment as previously described [14]. Briefly, a KDS200 syringe pump 
(KdScientific, USA) with an Alpha IV Brandenburg power source (Brandenburg, UK) was used.  Plastic 
syringes (1 ml; Becton Dickinson, UK) were used to contain and drive the solutions into 15-gauge 
blunt metallic needles (Intertronics, UK).  The applied voltage was 17 kV, the flow rate was 1 - 5 
ml/h, and the distance from the tip to the collector was set at 19 cm.  Polymeric solutions were 
prepared by dissolving PVP (10 wt%) and Eudragit RS100 (12.5 wt%) in 97 vol% EtOH (prepared in 
dH2O) and the solutions kept under continuous stirring at room temperature until the polymers 
were completely dissolved.  PEO (20 wt%) was then added to the polymeric solutions and stirred for 
a minimum of 30 minutes. Clobetasol-17-propionate was incorporated into the solutions by 
dissolving the required amount of the drug into EtOH prior to the addition of the polymers. Typically, 
electrospun membranes containing 1, 5 and 20 ʅŐǁĞƌĞƉƌŽĚƵĐĞĚand stored in a desiccator after 
manufacture. Before use, each batch of membranes was tested for total clobetasol-17-propionate 
content following total dissolution using HPLC and in all instances drug content was within ± 5% of 
the loaded dose.  
 
2.2.2 Preparation of backing layer 
A hydrophobic backing layer was prepared by electrospinning a 10 wt% solution of PCL on top of the 
drug delivery layer.  The solution was prepared by adding PCL to a blend of DCM and DMF (90:10 
vol% DCM:DMF), keeping the solutions under continuous stirring at room temperature until the 
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polymer had completely dissolved.  A thermal treatment (70°C for 10 minutes) was applied to the 
samples in order to enhance the attachment between both layers by gently clamping the two layers 
together and heating in a dry oven.  
 
2.3 Mucoadhesive patch characterisation 
2.3.1 Determination of film thickness, mass uniformity and pH 
The assessment of weight and patch thickness was completed on randomly selected patches from 
three independent batches. For determination of mass, patches were weighed on an electronic 
digital balance. Patch thickness was measured at 3 different randomly selected points using Vernier 
callipers and the pH determined by dissolving the patches in dH2O for 5 minutes and measurements 
recorded using a pH meter (Hanna Instruments, Rhode Island, US). 
 
2.3.2 Swelling index 
Patches were cut from the electrospun membranes (1.5×1.5 cm), weighed, and submerged into 5 ml 
of dH2O. After definite time intervals (30 seconds  ? 60 minutes) the patches were removed, excess 
moisture absorbed using tissue paper and reweighed. Increase in patch weight was determined at 
each time interval until a constant weight was observed. The degree of swelling was calculated using 
the formula: 
 (Wt  ? W0)    X 100   
     W0 
 
where, Wt is the weight of the patch at time t and W0 is the weight of the patch at time zero. 
 
2.3.3 Scanning electron microscopy 
Materials were imaged using a Philips XL20 scanning electron microscope (SEM). Samples were 
sputter coated with gold and imaged using an emission current of 15 kV. All images were processed 
using GNU Image Manipulation Program (GIMP, http://www.gimp.org) and Fiji20 software tools.  
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2.3.4 Differential thermal analysis 
Differential thermal analyses (DTA) of the bioadhesive patches and of clobetasol-17-propionate 
analytical standard (Sigma Aldrich, UK) were performed in a Perkin-Elmer Diamond DTA/TG system. 
Samples (10-15 mg) were loaded into platinum crucibles and heated from 50°C to 325°C at a rate of 
10°C/minute in a nitrogen atmosphere. The DTA patterns were processed using Perkin Elmer Pyris 
software and Microsoft Excel software. 
 
2.3.5 X-ray diffraction analysis 
X-ray diffraction (XRD) analyses of the electrospun membranes and of clobetasol-17-propionate 
analytical standard (Sigma Aldrich, UK) were performed in a PANalytical X'Pert³ powder 
spectrometer. Samples of the electrospun membranes (1 x 1 cm) were loaded on sample holders 
using Apiezon putty so that the surface of the specimen was level with the top of the specimen 
holder. Clobetasol-17-propionate was loaded on sample holders designed to hold powder samples. 
ůůƐĂŵƉůĞƐǁĞƌĞĂŶĂůǇƐĞĚŽŶƌĞĨůĞĐƚŝŽŶŵŽĚĞƵƐŝŶŐƵƌĂĚŝĂƚŝŽŶ ?ƐĐĂŶŶŝŶŐĂŶŐůĞƐƌĂŶŐŝŶŐĨƌŽŵ ? ? ?ɽ
ƚŽ  ? ? ?  ?ɽ ? ĂŶĚ ƐƚĞƉ ƐŝǌĞƐ ŽĨ  ? ? ? ? ? ?  ?ɽ ?  dŚĞ yZ ƐƉĞĐƚƌĂ ǁĞƌ  ƉƌŽĐĞƐƐĞĚ ƵƐŝŶŐ WEĂůǇƚŝĐĂů ĂƚĂ
Collector software and Microsoft Excel software. 
 
2.4.1 Cell culture  
Cell culture of immortalized oral keratinocytes FNB6-TERT immortalized oral keratinocytes (Beatson 
Institute for Cancer Research, Glasgow, United Kingdom; commercially available at Ximbio, London, 
United Kingdom) originally isolated from the buccal mucosa [24] ǁĞƌĞĐƵůƚƵƌĞĚŝŶ'ƌĞĞŶ ?ƐDĞĚŝƵŵ
ĐŽŶƐŝƐƚŝŶŐ ŽĨ ƵůďĞĐĐŽ ?Ɛ ŵŽĚŝĨŝĞĚ ĂŐůĞ ?Ɛ ŵĞĚŝƵŵ  ?D ? ĂŶĚ ,Ăŵ ?Ɛ & ? ? ŵĞĚŝƵŵ ŝŶ Ă  ? P ?  ?ǀ ?ǀ ?
ratio supplemented with 10% (v/v) fetal calf serum (FCS), 0.1 mM cholera toxin, 10 ng/ml epidermal 
growth factor, 0.18 mM adenine, 5 mg/mL insulin, 5 mg/ml transferrin, 2 mM glutamine, 0.2 nM 
triiodothyronine, 0.625 mg/mL amphotericin B, 100 IU/ml penicillin, and 100 mg/mL streptomycin. 
Normal oral fibroblasts (NOF) were isolated from the connective tissue of biopsies obtained from the 
buccal oral mucosa from patients during routine dental procedures with written, informed consent 
(ethical approval number 09/H1308/66) as previously described [25] and cultured in DMEM 
supplemented with 10% FCS, 2 mM glutamine, 100 IU/ml penicillin, and 100 mg/ml streptomycin. 
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2.4.2 Tissue-engineered oral mucosal equivalents 
Oral mucosal models were constructed as previously described [26]. NOF were added to rat tail 
collagen at a concentration of 2.5 x 105 cells/ml before adding 1 ml to 12 mm cell culture transwell 
inserts (0.4 mm pore; Merck Millipore, Darmstadt, Germany) and allowed to set in a humidified 
atmosphere at 37°C for 2 h. Inserts were submerged in growth media and incubated for 2 days, after 
which 2.5 x 105 FNB6 cells per model were seeded onto the surface. After a further 5 days, the 
models were raised to an air-to-liquid interface and cultured for 10 days to allow a fully stratified 
epithelium to form before use.  
 
2.4.3 Cytotoxicity and permeation studies using tissue-engineered oral mucosal  
To assess cytotoxicity a standard in vitro skin irritation test was performed according to OECD 
standards (OECD 439)[27]. Briefly, placebo or clobetasol-17-propionate loaded patches (1, 5 and 20 
µg) were applied, with gentle pressure, to the models and incubated for 1 h before removing, 
washing in PBS and the models cultured for a further 42 h in fresh medium. At this point, the models 
were washed in PBS and incubated in 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) (Sigma, Poole Dorset, UK) in PBS (0.5 mg/ml) for 3 hours. The solution was removed and 0.1 M 
HCl in 2-propanol added (2 ml) to each model with gentle agitation to dissolve the formazan crystals. 
Absorbance at 570 nm was measured using a spectrophotometer (Tecan, Männedorf, Switzerland). 
Data was processed using Microsoft Excel and expressed as viability relative to the negative control. 
For in vitro drug permeating studies, cell culture media was refreshed and placebo or clobetasol-17-
propionate loaded patches (1, 5 and 20 µg) applied to tissue-engineered models.  After 1 h 
incubation, the patches were removed, washed in PBS and weighed. The models were bisected and 
dissolved in collagenase IV (2 mg/ml) for 1 h. Both the dissolved model and receptive medium were 
analysed by high performance liquid chromatography (HPLC) to determine clobetasol-17-propionate 
content. HPLC analysis was performed using a Waters 2690 HPLC with a Zorbax RX-C18 250 mm x 4.6 
mm column and a mobile phase composed of acetonitrile (ACN)/water: CP (45% of ACN in water for 
15 minutes, ramping to 100% ACN after 16 minutes) at 1 ml/min. UV was measured using Waters 
486 UV/dis detector at 240 nm. For each concentration, single injections were made to obtain the 
peak area for constructing the calibration curve. 
 
2.4.4 Histological analysis 
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For histological processing, the insert containing the tissue-engineered models were removed from 
the culture medium, washed with PBS and fixed in 10% buffered formalin overnight. The entire 
model (connective tissue and epithelium) was removed from the transwell insert along with the 
polycarbonate filter, subjected to routine histological processing, and paraffin-wax embedded. Five-
micrometre sections were cut by using a Leica RM2235 microtome (Leica microsystems) and stained 
with haematoxylin and eosin. 
 
2.5 In vivo residence time and patch acceptability 
Twenty-six volunteers who satisfied the inclusion and exclusion criteria (Supplementary Figure 1) 
were recruited with written, informed consent after approval from the University of Sheffield Ethical 
Committee. Following the international standard of Good Clinical Practice, placebo patches (25.4 x 
12.7 mm) were applied to the lateral tongue, buccal and gingival mucosa for 5 seconds with applied 
pressure. Patch adhesion was monitored every 10 minutes for 2 hours and residence time recorded 
for each location. The residence time was taken as the time for the patch to completely dislodge 
from the site where the patch had been placed.  At the end of the study, an acceptability 
questionnaire was completed by all volunteers to collect information regarding parameters of the 
patch such as irritancy, comfort, taste, dry mouth and salivation. Food and drink intake was not 
allowed for 1 hour prior to beginning the study and until the study was complete.  
 
2.6 In vitro drug dissolution   
The release of clobetasol-17-propionate from the mucoadhesive patches manufactured with a range 
of concentrations (1, 5 and 20 µg) was determined using Erweka DT80 dissolution apparatus in 
conjugation with paddle stirrers, according to Ph. Eur. method 2.9.3. In brief, the patches were 
attached to supports and lowered into the dissolution vessels containing dissolution medium (0.5 M 
phosphate buffer saline and 0.5% sodium dodecyl sulphate, pH 6.8 at 37°C). The medium was stirred 
at a constant rate of 100 ± 2 rpm and at pre-determined intervals (15-360 minutes) samples of 
dissolution fluid (2 ml) were removed and replaced with an equal volume of fresh, pre-warmed 
dissolution fluid. The concentration of clobetasol-17-propionate in the samples of dissolution fluid 
were analysed by reverse phase HPLC with reference to a previously constructed calibration curve 
(r2>0.99).  
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2.7 Ex vivo drug permeation through the oral mucosa 
Mucosa (2.5 x 2.5 cm), freshly prepared from whole porcine cheeks (Citoxlab Scantox A/S, Lille 
Skensved, Denmark) were mounted in a Franz cell (7 ml receiver volume of PBS, exposure area of 2.3 
cm2, 37°C), wetted with PBS (50 µl) and patches (1.2 x 1.2 cm) applied with gentle pressure to the 
mucosal surface. After three hours, the patches were removed, a 1 ml sample of the acceptor buffer 
collected and the mucosa rinsed with PBS to remove residual clobetasol-17-propionate present on 
the surface. To calculate the amount of drug within the mucosa, the mucosa pieces were first heated 
to 65 °C for three minutes to enable removal of the epithelial layer of the mucosa, which was 
subsequently cut into smaller pieces and placed in acetonitrile (1 ml) and treated with ultrasound for 
10 minutes before filtering (0.22 µm cellulose acetate filter) for analysis. Both the collected receiver 
buffer and acetonitrile were analysed for the concentration of clobetasol-17-propionate by HPLC 
using a Kinetex C18-XB 100x4.6, 5µ column at 40 °C, in MilliQ water: acetonitrile, Isocratic elution; 
(ratio 30:70) with an injection volume of 5 µl and flow rate of 0.5 ml/min, coupled to a UV-detector 
(237 nm) and a MS-detector (Electrospray: Negative, SIM Ions: 501.2, 503.0. Fragmentor: 70 drying 
gas flow: 12 L/min, drying gas temperature: 250 °C, nebulizer pressure 35 psig, vaporizer 
temperature 200 °C, capillary voltage 4000 V). 
 
2.8 In vivo residence time and local tolerance of clobetasol-17-propionate loaded patches in minipigs.  
All animal studies were conducted at CiToxLAB Scantox A/S (Lille Skensved, Denmark) in accordance 
with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for 
Human Use and European Medicine Agency guidelines; (EMA/CPMP/ICH286/1995, December 2009; 
CPMP/ICH/384/95, June 1995 and CPMP/SWP2145/00, March 2001). Six female Göttingen SPF 
minipigs (Ellegaard Göttingen Minipigs A/S, Dalmose, Denmark) weighing 12-18 kg were used. A 
phase 0 study was conducted to determine experimental residence time. Patches were applied to 
the cheek of three anaesthetised (1 ml/10 kg body weight of Zoletil 50®Vet; Virbac, France) minipigs 
and the patches visually examined for patch detachment for up to 240 minutes. Residence time was 
recorded as the time when the patch had completely detached from the mucosa. In phase 1 and 2, 
patches were applied to each cheek of six anaesthetised minipigs randomised to one of two study 
groups for treatment with either 5 or 20 µg clobetasol-17-propionate-loaded mucoadhesive patches. 
To determine local systemic tissue pharmokinetics (phase 1), 3 ml blood samples were collected 
prior to patch application and also at 30, 60, 120 and 240 minutes (the time of patch removal) and 
additionally at 360 minutes post patch application (2 hours after patch removal). Samples were 
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centrifuged (10 minutes at 1600 g, 4°C) and plasma removed and stored at -70°C prior to analysis. To 
determine local systemic tissue pharmokinetics (phase 2), after an eight-day washout period, 
patches were applied and two tissue biopsies (8 mm biopsy punch) taken from each patch 
application site at 30, 60, 120 and 240 hours post application. Biopsies were weighed, snap frozen 
and stored at -70°C prior to analysis. Clobetasol-17-propionate concentrations in plasma and biopsy 
samples were determined using protein precipitation followed by solid phase extraction, 
evaporation and reconstitution with analysis of the supernatant by LCMS/MS using multiple reaction 
monitoring; data are expressed as µg/biopsy. 
 
2.9 Data analysis  
Results are presented as mean ± standard deviation unless otherwise stated. ANOVA with the Tukey 
multiple comparisons post-hoc test was used to compare differences between groups. Statistical 
analysis of all data was carried out using Graphpad prism version 7.0 (Graphpad software Inc., San 
Diego, California, USA) and results were considered statistically significant if p<0.05. All experiments 
were conducted at least in triplicate. 
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3. Results 
3.1 Mucoadhesive characteristics and evaluation of mucosal toxicity of the placebo patch 
Mucoadhesive patches were manufactured by electrospinning PVP (10 wt%), RS100 (12.5 wt%) and 
PEO (Mw 2,000 kD; 20 wt%) to yield a patch with final dry mass ratio of 1:1.25:2 for PVP:RS100:PEO 
with a PCL backing layer to create a dual-layer system. Patches assessed from 3 different batches 
were observed to have uniformity of mass with an average weight of 55.3 ± 5.18 mg (Figure 1A) and 
an average thickness of 0.43 ± 0.028 mm (Figure 1B). The values for surface pH were consistently in 
the range of 8.2 ± 0.38, close to that of saliva, indicating that the patches are suitable for application 
to the oral mucosa (Figure 1C). The degree of swelling was rapid with the patches taking on 50% of 
their weight within 3 minutes followed by a steady swelling rate up to one hour, when the patch had 
increased in weight by 65%. (Figure 1D). SEM images revealed a smooth PLC backing layer that was 
tightly adherent to the mucoadhesive layer, which displayed electrospun fibres homogeneous in 
number, diameter and alignment (Figure 1E). 
Before testing in a volunteer human study, cytotoxicity of the placebo patch was evaluated in tissue-
engineered models of the oral mucosa following OECD guidelines. MTT analysis revealed that the 
placebo patches did not reduce viability compared to the media only control after a 1 hour 
incubation period and can therefore be classified as non-irritant according to OECD guidelines 
(Figure 1G). This data was supported further by histological examination of the tissue-engineered 
mucosal models that revealed no damage or loss of integrity of the epithelium after incubation with 
the patches (Figure 1H).  
3.2 In vivo mucoadhesive performance and acceptability of the placebo patch  
In vivo residence time and patch acceptability was assessed in 26 healthy adult volunteers (15 male 
11 female) aged between 21 and 64 years (mean 34 ± 3.8); all volunteers were non-smokers. 
Residence time was recorded for three locations within the oral cavity; upper labial gingiva, lateral 
border of tongue and buccal mucosa (Figure 2A-C) to a maximum of 120 minutes. Residence times 
were highest for the gingival applied patches followed by those on the buccal mucosa with 96% and 
46% of patches remaining adherent for the full 120 minutes, respectively. No patches remained 
attached to the tongue for the full 120 minutes. Average residence times were 118 ± 5, 43 ± 26 and 
96 ± 26 minutes for gingiva, tongue and buccal mucosa, respectively (Figure 2D). In terms of 
partŝĐŝƉĂŶƚƐ ?ƉĞƌĐĞƉƚŝŽŶŽĨƚŚĞƉĂƚĐŚ ?96% of volunteers responding positively with good, very good 
or excellent when asked to rate the overall adherence of the patches and over 88% of volunteers felt 
little or no irritation whilst wearing the patches (Table 1).  
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With regards to patch specifics, 88% of volunteers thought the size of the patches were appropriate 
with over 65% stating that they thought the patch appearance was good/very good or excellent. All 
volunteers agreed that the patches had none or a weak taste that was neither pleasant nor 
unpleasant. Over 85% of volunteers thought that the method of application was acceptable and that 
removal was easy. The majority of volunteers (>70%) stated that overall the patches were not 
bothersome to wear on the gingiva and buccal mucosa but the tongue was more bothersome with 
53% finding it moderately so. Some participants (23%) reported moderate or somewhat interference 
with speech, although over 60% stated only minor effects on saliva production and swallowing. 84% 
of volunteers responded positively stating that they would be willing to wear the patch twice-a-day 
to treat an oral lesion if required (Table 1). 
3.3 Physiochemical characterisation of clobetasol-17-propionate loaded mucoadhesive patches 
Clobetasol-17-propionate-loaded patches, assessed from 3 different batches, were observed to have 
an average weight of 67.4 ± 5.1, 59.0 ± 3.7 and 53.0 ± 3.2 mg for the 1, 5 and 20 µg clobetasol loaded 
patches, respectively; weight differences were not significant (Figure 3A).  Average thickness of the 
patches was 0.51 ± 0.05, 0.36 ± 0.02 and 0.45 ± 0.032 for the 1, 5 and 20 µg clobetasol loaded 
patches, respectively (Figure 3B). The values for surface pH were consistently between 8.0 and 8.1 
for the different clobetasol-17-propionate concentrations (Figure 3C).  
The degree of swelling for the clobetasol17-propionate loaded patches was slightly slower, although 
not-significantly, than for the placebo patches with the patches taking on 50% of its weight within 24 
minutes for the 1 µg patch and 14 minutes for both the 5 and 20 µg patches. All patches increased in 
weight to approximately 70% of their own weight within 60 minutes (Figure 3D). SEM images 
revealed no change in ultrastructure with the addition of clobetasol-17-propionate with the 
electrospun fibres remaining homogeneous in alignment, diameter and number (data not shown). 
The DTA curve for clobetasol-17-propionate shows a clear peak at 226°C, which corresponds to the 
melting point for clobetasol-17-propionate (www.drugbank.ca/drugs/DB01013).  The curves of the 
electrospun membranes did not present a peak at this location but both materials presented a peak 
at 73°C that is not present in clobetasol-17-propionate alone (Figure 3E).  Both electrospun materials 
produced very similar XRD patterns.  The pattern produced by clobetasol-17-propionate alone 
showed several peaks, evidence of a significantly more crystalline structure, peaks that were absent 
in the pattern of the electrospun material containing 2.31 wt% of drug (Figure 3F), suggesting that 
the clobetasol-17-propionate is in an amorphous form within the electrospun fibres. 
3.4 In vitro drug dissolution 
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No difference was observed in the clobetasol-17-propionate release profile from patches loaded 
with 1, 5 or 20 µg of the drug. All the drug loaded patches slowly released the clobetasol-17-
propionate in a sustained manner over a 6 hour period with approximately 20%, 50% and 80% 
released after 30, 180 and 360 minutes, respectively (Figure 4A). Reproducibility between batches 
was high with no difference in the percentage of clobetasol-17-propionate propionate released 
observed between two independently manufactured 5 µg patches (Figure 4B).  
3.5 In vitro drug loaded patch cytotoxicity and in vitro and ex vivo drug permeation analysis 
Clobetasol-loaded mucoadhesive patches were applied to the epithelial surface of a tissue-
engineered oral mucosa for one hour (Figure 5A) and then mucosal equivalents tested for 
cytotoxicity using the OECD irritancy assay.  There was a small but non-significant reduction in tissue 
engineered mucosal viability to 76.8 ± 10.3, 71.2 ± 18.4 and 74.6 ± 24.4 for the 1, 5 and 20 µg 
patches, respectively, which is above the 50% threshold and therefore considered to be a non-
irritant in accordance with the OECD guidelines (Figure 5B). In addition, histological analysis revealed 
no epithelial damage after application and removal of the clobetasol-17-propionate-loaded patches 
compared to placebo controls (Figure 5C).  
To ascertain drug release and permeation in physiologically relevant tissues, tissue-engineered oral 
mucosal equivalents and ex vivo porcine mucosa were employed. Drug permeation in to the tissue-
engineered oral mucosal equivalents was assessed after a one hour incubation period by tissue 
homogenization followed by HPLC analysis.  The amount of clobetasol-17-propionate found in the 
epithelium increased as the initial loading concentration increased with 66, 121 and 312 nM/mg 
detected in the epithelium after 1 hour (Figure 5D). Interestingly, clobetasol was only detected in the 
receptor medium when a 20 µg patch was applied to the epithelium, the amount detected was low 
at 16 nM (data not shown). 
Clobetasol-17-propionate permeation into ex vivo porcine mucosa was also investigated for three 
different doses (1.25, 5 and 25 µg) but for a longer time period of three hours. HPLC analysis 
revealed that the drug was able to permeate into porcine buccal mucosa in a dose-dependent 
manner with significantly (p<0.01) more clobetasol-17-propionate delivered into the mucosa for the 
25 µg patch (1484 ± 690.8 µg/g of patch) than for the 1.25 and 5 µg patches (124 ± 63 and 237 ± 68 
and µg/g of patch respectively) (Figure 5E). 
3.7 In vivo residence time and local physiochemical permeation of clobetasol-17-propionate in 
mini-pig mucosa 
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In vivo adhesion to the buccal mucosa for the clobetasol-17-propionate patch (5 µg) showed an 
average residence time of 184 ± 45 minutes in mini-pigs (Figure 6A). Local tissue physiochemical 
analysis revealed that clobetasol-17-propionate permeation into mini-pig buccal mucosa for the 5 µg 
patch was low (~10 ng/biopsy) after 30 minutes that was sustained for up to 240 minutes. In 
contrast, release from a 20 µg patch was significantly greater (p<0.01) after 30 minutes. However, 
levels of clobetasol-17-propionate released into the oral mucosa then declined and were not 
significantly different to the 5 µg patch at later time points (Figure 6B). Plasma analysis revealed that 
systemic exposure was below the level of detection (20 pg/ml) at the time points investigated (up to 
six hours).  
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Discussion 
Oral lesions, including those such as OLP and RAS, are prevalent in society and can impart a 
significant burden on quality of life. These lesions are usually treated using topically applied 
corticosteroids but current drug delivery systems are inadequate and new ways of delivering these 
therapeutic agents directly to lesions are required. Controlled delivery of drugs to the oral mucosa is 
challenging because of moist mucosal surfaces, salivary flow and abrasive forces within the oral 
cavity. To overcome these obstacles we recently developed an innovative dual-layered electrospun 
mucoadhesive patch [14]. Here, we expand this work and report the first use and acceptability of our 
optimised, drug-free electrospun mucoadhesive patch in humans. We also show drug loading and 
both in vitro and in vivo drug release profiles of these dual-layer patches. 
The use of electrospun nanofibers manufactured from a variety of polymers is becoming increasingly 
popular as a way of improving adhesion of patches to biological surfaces and to control drug release. 
This is because electrospun nanofibers have increased surface area, high porosity and are amenable 
to incorporation of bespoke polymer characteristics compared to current film formulations [28].   
We recently developed a complex mucoadhesive electrospun dual-layer system comprised of FDA 
approved polymers that consists of a bioadhesive layer containing hybrid PVP, Eudragit®RS100, PEO 
nanofibers and a hydrophobic protective backing layer made from thermally-treated PCL nanofibers 
[14]. These patches show a high level of consistency for weight, thickness and nano-fibre structure. 
In addition, the pH of the patches was ~ 8.2, slightly more alkali than that of saliva (pH 5.6 ?7.9) but 
deviation not significant enough for these patches to cause irritation or cytotoxicity. 
Nano-fibre swelling is a crucial property for bioadhesion. Successful mucoadhesion of electrospun 
patches critically relies upon the rapid hydration and subsequently gelation of the nano-fibres at the 
moist mucosal surface [29]. Our electrospun patch displayed extremely quick and sustained swelling 
over 60 minutes, a profile suitable for rapid and prolonged mucoadhesion. Indeed, when applied 
with gentle finger pressure, our malleable electrospun patches adhered rapidly to human gingival 
and buccal mucosa, and tongue epithelium, common sites for OLP and RAS lesions.  In vivo residence 
time, recorded for up to 120 minutes, in human volunteers with healthy mucosa was longest for 
gingivae (118 minutes) then buccal mucosa (93 minutes) and then tongue (43 minutes); data that 
suggest adhesion strength is linked to the tissue-specific mechanical stresses or degree of epithelial 
keratinisation. Very few studies have examined the adhesion of electrospun patches to human oral 
mucosa in vivo. Although, Samprasit et al showed rapid swelling properties of their thiolated-
chitosan sulphate (CS) and polyvinyl alcohol (PVA) blended electrospun patches and adhesion to ex 
vivo porcine mucosa; these patches only achieved a residence time of 5 minutes when applied to 
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human buccal mucosa [11] and suggest that the polymer blend as well as increased surface area 
provided by electrospinning is critically important for adhesion to human mucosa. Several similar 
human in vivo adhesion studies have been performed using adhesive films comprised of various 
polymer formulations and blends where different degrees of in vivo residence times have been 
observed, with times being either comparable to or below those presented in this study [30-32]. The 
adhesion studies described herein were performed in the absence of food or water intake. Although 
we have no empirical evidence, it is possible that the consumption of food or water whilst wearing 
the oral patch may reduce its adhesiveness and therefore impact on drug release. Therefore, we 
envisage that individuals using these patches will be asked to refrain from food and liquid intake for 
the duration of treatment. 
Overall perception of the adhesiveness of our electrospun patches from healthy volunteers was 
rated as good, very good or excellent with the majority stating that the patches were appropriately 
sized, had an acceptable appearance and displayed either no taste at all or a weak neutral taste.  
Moreover, the majority of volunteers did not feel that the patches interfered with their speech, 
saliva production or swallowing, indicating that our patches are highly acceptable for human use.  
The best treatment for many oral lesions remains use of topical corticosteroids, with clobetasol-17-
propionate arguably showing greatest efficacy [19-22]. Clobetasol-17-propionate has been 
successfully incorporated into other polymer nanosystems including lecithin/chitosan nanoparticles 
[33] polymer-coated nanocapsules [34] lipid nanoparticles [35] but these systems are all aimed at 
drug delivery to skin. Therefore, we chose to incorporate clobetasol-17-propionate within the 
electrospun adhesive layer of our patches as the pharmacologically active agent for oral delivery.  
Addition of clobetasol-17-propionate to the patches had no effect on any of the physiochemical 
properties investigated including weight, thickness, pH and swelling index.  Both XRD and DTA 
analysis show that within electrospun patches the clobetasol-17-propionate is in an amorphous 
rather than crystalline state.  Similar observations have been reported for a number of electrospun 
polymer combinations containing a myriad of agents such as the anti-microbials clotimazole [15] and 
ɲ-mangostin [11], non-steroidal anti-inflammatory drugs, ibuprofen [36] and aceclofenac [37] and 
the corticosteroid budesonide [38]. In contrast, Vacanti et al and Hsu et al both observed that the 
corticosteroid dexamethasone remained in the crystalline state in their electrospun polymer systems 
[39, 40], suggesting that either not all corticosteroids will convert to the amorphous state or, more 
likely, that the polymer blend and manufacturing conditions are crucial for this process to occur. It is 
well appreciated that the amorphous state of a compound possesses several advantages including 
enhanced solubility and increased dissolution rate to its crystalline counterpart, therefore the 
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presence of the amorphous form of clobetasol-17-propionate in our electrospun system offers a 
distinct advantage for increased drug delivery.  
 
The selected doses of clobetasol-17-propionate used in this study were intended to replicate the 
current dosing regimens of gels and creams used in the topical delivery for treatment of dermal 
inflammatory disease. Dermal dosing typically is imprecise, based on the fingertip-unit that is 
equivalent to 0.4-0.5 g covering 100-150 cm2. Current formulations for dermal use contain 0.05% 
clobetasol-17-propionate, which once applied as a fingertip unit, results in approximately 1.33-2.5 
µg/cm2. To replicate this dosage, 3.1 cm2 patches were fabricated with 0.0004%, 0.002% or 0.008% 
clobetasol-17-propionate to create patches that contained a total drug content of 1, 5 and 20 
µg/patch, respectively.  
In vitro release profiles of patch-loaded clobetasol-17-propionate demonstrated fast but sustained 
release with approximately 80% of the drug liberated within 360 minutes. The polymer composition 
of electrospun mats or patches is crucial in determining drug release kinetics. Dott et al, showed that 
in vitro release of the antihistamine diphenhydramine by PVA electrospun patches was rapid with 
86% released after 3 minutes [17]. Similarly, Vacanti et al showed that 50% of dexamethasone was 
release from PCL electrospun fibers in vitro after 20 minutes and 100% after 90 minutes, whereas 
release of this steroid was much slower with poly(L -lactic) acid fibers with 100% being released after 
1 month [39]. Rapid, in vitro burst release drug profiles have also been observed for CS/PVA single or 
blended electrospun fibres [11, 15, 41]. The initial burst release is not only related to the 
physicochemical properties and concentration of the drug but also polymer formulation of the 
electrospun fibres [28]. Indeed, Kathikeyan et al showed that addition of Eudragit RS100 to zein 
electrospun nanofibres significantly prolonged release of aceclofenac by several hours compared to 
zein alone nanofibres [37], implying that inclusion of Eudragit RS100 in our electrospun fibre 
polymer blend allows for improved sustained in vitro drug release compared to previous drug-
loaded electrospun systems.  
Tissue engineered models of the oral mucosa are increasingly being used as surrogate models to 
assess tissue irritancy, toxicity and transepithelial drug delivery [42]. Application of clobetasol-17-
propionate-loaded electrospun patches containing up to 20 Pg/ml did not show any toxic or irritant 
effects on tissue engineered oral mucosal models as assessed using the OECD irritancy test and by 
histological examination of tissue, suggesting that even relatively concentrated forms of clobetasol-
17-propionate do not cause tissue damage on contact with the epithelium. Moreover, tissue 
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profiling for clobetasol-17-propionate content by HPLC in both in vitro tissue engineered and ex vivo 
porcine mucosa show a dose-dependent release of steroid into the tissue, with the 20 Pg/ml 
clobetasol-containing patch showing the greatest release into these tissue. Quicker drug release was 
obtained using PVA electrospun patches containing diphenhydramine on ex vivo porcine mucosa 
where 78% of drug permeated the mucosal tissue within 3 minutes [17]. In contrast, sumatriptan (a 
drug used in the treatment of migraine)-loaded PVA electrospun porcine sublingual drug delivery 
was just 1%, whereas PCL or CS electrospun patches loaded with the non-steroidal anti-
inflammatory drug Naproxen were able to release up to 50% of their cargo to the sublingual mucosa 
within 5 hours [41]. Once again these data show that both the polymer nanofibre blend as well as 
physiochemical properties of the drug are essential for efficient mucosal drug delivery.   
Finally, we applied clobetasol-17-propionate-loaded electrospun patches to mini-pig buccal mucosa 
as an in vivo model of drug delivery. Interestingly, in vivo buccal residence time in minipigs was 
similar to that observed in humans. Here, marked levels of clobetasol-17-propionate were detected 
in the mucosal epithelium after just 30 minutes application using the 20 Pg/ml loaded patch where 
upon levels declined by 60 minutes but remained constant for up to 240 minutes. Although these 
data may not be directly related to the human setting since porcine mucosa epithelium is 3 times 
thicker than in humans [43], they clearly show release of steroid from the electrospun patch into the 
epithelium in vivo.  
Previous studies examining the delivery of clobetasol-17-propionate to the dermis using a tape-strip 
pig ear model showed that the steroid was retained in the stratum cornea with little present in the 
rest of the epithelium [44, 45]. Since the buccal oral mucosa does not possess a stratum corneum, it 
is likely that the clobetasol will pass without hindrance into the entire oral epithelium. In support of 
this we did not observe substantial retention of clobetasol-17-propionate in the mucosa over time in 
our mini-pig in vivo studies. A further reason for the disappearance of clobetasol17-propionate from 
the mucosa may be due to its metabolism into undetectable metabolite forms by xenobiotic 
cytochrome p450 enzymes that are likely to be expressed in the epithelium [46, 47]. 
One of the main risks with using long-term, highly potent corticosteroid therapy is the potential for 
these compounds to induce suppression of the hypothalamic-pituitary-adrenal (HPA) axis if high 
plasma levels are maintained. It is difficult to determine maximal dose ranges due to person-to-
person variability, and although there is currently no cut-off concentration for clobetasol-17-
propionate, data suggest that dosages as low as 25 g of 0.05% cream applied to the skin per week 
may affect the HPA axis [48]. The serum absorption of 0.05% clobetasol-17-propionate-containing 
emulsion on normal skin was previously found to be between 1 to 6 ng/ml [49], suggesting that 
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topical delivery of clobetasol-17-propionate may reach serum levels that could potentially cause off-
target effects. The oral mucosa is more permeable than skin and so up-take is likely to be greater for 
oral delivery. Indeed, Varoni et al observed that patients with oral lesions taking long term 0.05% 
clobetasol-17-propionate treatment (ointment or within hydroxyethylcellulose gel) had serum levels 
of around 1.5 ng/ml potentially placing them at high risk [23]. However, in a volunteer study, these 
authors showed that although clobetasol-17-propionate was able to pass more quickly through 
damaged than healthy oral mucosa when applied topically (0.05% in 4% hydroxyethylcellulose gel), 
the serum levels of the drug were just 0.2 ng/ml. We could not detect clobetasol-17-propionate in 
serum samples taken from mini-pigs wearing clobetasol-ůŽĂĚĞĚƉĂƚĐŚĞƐ ? ? ?ʅŐ ?ĂƉƉůŝĞĚƚŽƚŚĞďƵĐĐĂů
mucosa over 4 hours, and although this needs to be confirmed in humans, these data suggest that 
electrospun patch-delivered clobetasol-17-propionate will not affect the HPA axis.  
While the high surface area: volume ratio of electrospun fibres is a potentially attractive feature for 
site specific drug delivery, this approach is not possible without adhesion to the mucosal surface. 
Indeed, the moist environment in the human mouth presents a major challenge that, until now, has 
prevented the successful direct delivery of drugs to oral lesions via adhesive devices. The data 
presented here demonstrates that the combination of drug loaded electrospun fibres with a 
hygroscopic polymer facilitates long term adhesion that leads to successful local delivery of a potent 
steroid. This work therefore demonstrates the utility of a new class of adhesive devices to address 
the challenge of local drug delivery to mucosal surfaces including within the oral cavity. It is 
predicted that these devices have the potential to introduce a step change in improved healthcare in 
oral medicine, and clinical evaluation is strongly recommended. 
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Figure Legends  
Figure 1: Mucoadhesive placebo patch characteristics and evaluation of mucosal toxicity. 
Electrospun mucoadhesive placebo patches were characterised from three different batches for (A) 
weight, (B) thickness, (C) pH and (D) swelling (n=8). Scanning electron microscope micrographs of 
the (Ei) PCL backing layer, (Eii) a cross section of the patch showing adherence of the impermeable 
PLC (lower most layer) backing layer to the underlying mucoadhesive layer (upper most layer; PVP 
10 wt%, RS100 12.5 wt% and PEO 20 wt%) (Eiii) with mucoadhesive layer fibres homogeneous in 
diameter and alignment. (F) Cytotoxicity testing of the placebo patch using tissue-engineered oral 
mucosa equivalents revealed that they do not cause cytotoxicity compared to media only controls 
(SDS treatment used as positive control). Histological examination also confirmed that there was no 
evidence of damage or loss of integrity to the epithelium after (Gi) a 1 hour incubation period 
compared to (Gii) media only control. The swelling data is presented as mean ± SEM. n=6 Scale bars= 
20 and 100 µm.  
 
Figure 2: In vivo mucoadhesive performance of placebo patch. Mucoadhesive patches were placed 
on the (A) gingiva, (B) lateral tongue or (C) buccal mucosa of healthy human volunteers for 5 seconds 
with applied pressure and (D) residence time measured every 10 minutes for up to 2 hours. 
sŽůƵŶƚĞĞƌƐ ? ƌĞƐƉŽŶƐĞƐ when asked to rate the perception of overall (E) patch adherence and (F) 
irritation to the mouth (n=26). 
 
Figure 3: Clobetasol-17-propionate loaded patch characterisation. Electrospun mucoadhesive 
patches loaded with clobetasol-17-propionate (1, 5 and 20 µg) were characterised from three 
different batches for (A) weight, (B) thickness, (C) pH and (D) swelling (E) Differential thermal 
analysis and (F) X-ray diffraction patterns of soluble clobetasol-17-propionate, a placebo patch and a 
clobetasol loaded patch. The weight, thickness and pH data is presented as mean ± SEM (n=8) and 
the swelling data is presented as mean ± SEM (n=5). 
 
Figure 4: Dissolution of clobetasol-17-propionate from the mucoadhesive patches. (A) Clobetasol-
17-propionate dissolution from patches loaded with differing concentrations of the drug (1, 5 and 20 
µg) revealed a sustained release profile over a six-hour period. (B) Reproducibility between 
23 
 
manufacturing batches was high with no difference in the percentage of clobetasol-17-propionate 
released observed between the patches.  
 
Figure 5: Cytotoxicity and in vitro/ex vivo clobetasol-17-propionate permeation into oral mucosa. 
(A) Cytotoxicty testing of the patches using tissue-engineered oral mucosa equivalents using a MTT 
assay (B) revealed that the although the drug loaded patches reduced viability by approximately 25% 
they were not considered cytotoxic and histological examination confirmed that there was no 
evident damage or loss of integrity to the epithelium after an one hour incubation period from 
either the (Cii) 1 µg, (Ciii) 5 µg or (Civ) 20 µg when compared to (Ci) placebo patch. Clobetasol-17-
propionate levels extracted from (D) tissue-engineered oral mucosal equivalents or (E) ex vivo 
porcine oral mucosa determined using HPLC after a one or three hour adhesion period of the drug 
loaded patches (1, 5 and 20 µg or 1.25, 5 and 25 µg), respectively (n=4) ** p<0.01.  Scale bar = 100 
µm. 
 
Figure 6: In vivo residence time and local tissue release of clobetasol-17-propionate patches. (A) 
Average residence time of clobetasol-17-propionate loaded patches to the buccal mucosa in 
minipigs over a 4 hour time period (n=3). (B) Clobetasol extracted from the buccal mucosa 
(ng/biopsy) of minipigs after 30, 60, 120 and 240 minutes from 5 µg (B) and 20 µg (C) loaded patches 
with a surface area of 3.12 cm2 (n=6). 
 
Table 1: Response of healthy human volunteers to various parameters of the patches. 
 
Supplementary figure 1: Inclusion and exclusion criteria for the human volunteer study. 
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